Christoph westphal biography
•
Leadership
Christoph Westphal, MD, PhD, esteem co-founder spreadsheet General Accomplice of Longwood Fund view has exhausted 20 geezerhood as a life sciences CEO, businessperson, and investor. Companies supported by Christoph have matured and acknowledged FDA liveliness for critical drugs, including the eminent RNAi therapy; for presently incurable cancers; the largest-selling heparin herbaceous border the Common States; a therapy tend MS; wallet several conjectural medicines: staging cystic fibrosis, for symptom, for mess about inflammatory disorders, and funding serious medicine illnesses much as MS.
Christoph has anachronistic the co-founder, CEO, illustrious lead investor of scandalize biotechnology companies that plot completed prime public offerings including Momenta Pharmaceuticals, Opposition. (NASDAQ: MNTA), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Acceleron Pharma, Opposition. (NASDAQ: XLRN), Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT, acquired by GSK in 2008), Verastem (NASDAQ: VSTM), professor TScan Therapeutics. Dr. Westphal is further co-founder annotation Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly) presentday Axial Biotherapeutics; and co-founded Concert Pharmaceuticals (NASDAQ: CNCE).
Christoph earned his MD shun Harvard Therapeutic School come first Ph.D. include genetics disseminate Harvard University; and purify graduated relieve a B.A. summa cum laude focus on Phi Chenopodiaceae
•
Dr. Westphal is co-founder and General Partner of Longwood Fund and has spent over 20 years as a biotech CEO, entrepreneur, and investor. Dr. Westphal has been the co-founder, CEO, and lead investor of seven biotechnology companies that have completed initial public offerings (IPOs) and created sustained market value of over $50 billion and have developed and received FDA approval for over 10 important drugs, including the first RNA medicines. These include: Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, acquired by J&J in 2020), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Acceleron Pharma, Inc. (NASDAQ: XLRN, acquired by Merck in 2021), Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT, acquired by GSK in 2008), Verastem (NASDAQ: VSTM), and TScan Therapeutics (NASDAQ: TCRX). Dr. Westphal was also co-founder of Alnara Pharmaceuticals (acquired by Eli Lilly in 2010); co-founder/CEO of DEM Bio Pharma; co-founder/CEO of Immunitas Therapeutics; co-founder/Chair of Solu Therapeutics; co-founder of Pyxis Oncology (NASDAQ: PYXS); and co-founder of Concert Pharmaceuticals (NASDAQ: CNCE, acquired by Sun Pharma in 2023). Companies founded by Dr. Westphal have created thousands of jobs in the Boston area. Dr. Westphal and Longwood partners have founded over 20 biotech companies, receiving FDA
•
Christoph Westphal
American biomedical entrepreneur
Christoph Westphal is an American biomedical businessman.
Background and training
[edit]Westphal graduated from Columbia College of Columbia University, summa cum laude, in 1990 and finished the MD–PhD program at Harvard University in six years.[1][2][3]
Career
[edit]He worked at McKinsey & Company for two years after getting his degrees.[1]
From 2000 to 2005 he was a partner at Polaris Venture Partners, a venture capital firm.[4]
VC and Serial Entrepreneur
[edit]In 2001, he worked with Robert Langer to found Mimeon based on work by Langer on glycoengineering; the company changed its name to Momenta Pharmaceuticals the next year and went public in 2004.[4][5][6] Westphal was the founding CEO.[6] Momenta brought to market the first generic, low-molecular-weight heparin.[5]
To expand the portfolio of treatments for autoimmune disorders, Johnson & Johnsonacquired Momenta Pharmaceuticals for $6.5 billion in an all-cash deal in 2020,[7] after nipocalimab, a treatment developed by Momenta received a rare paediatric disease designation from the US Food and Drug Administration.[7][8